First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study

First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study

Background The phase III, randomized, open-label ENSURE study (NCT01342965) evaluated first-line erlotinib versus gemcitabine/cisplatin (GP) in patients from China, Malaysia and the Philippines with epidermal growth factor receptor (EGFR) mutation-positive non-small-cell lung cancer (NSCLC). Pati...

Full description

Bibliographic Details
Main Authors: Wu, Y-L, Zhou, C.., Liam, Chong-Kin, Wu, G., Liu, X., Zhong, Z., Lu, S., Cheng, Y., How, Soon Hin, ., et al.
Format: Article
Language:English
English
Published: Oxford University Press on behalf of the European Society for Medical Oncology 2015
Subjects:
RC Internal medicine
Online Access:http://irep.iium.edu.my/44211/
http://irep.iium.edu.my/44211/
http://irep.iium.edu.my/44211/
http://irep.iium.edu.my/44211/2/firstline_erlotinib.pdf
http://irep.iium.edu.my/44211/6/44211_First-line%20erlotinib%20versus%20gemcitabine_SCOPUS.pdf

Similar Items

Similar Items